Pharma company Granules India is planning seven new launches in the regulated markets. These new products are expected to serve as key drivers for growth over the next four quarters.

Highlighting the scope of this expansion, Priyanka Chigurupati, Executive Director of Granules Pharmaceuticals, said these are essentially for the US Europe, Canada, and the UK. "These are the launches that we will start in Q3, and Q4, the full effect of which will fill in FY25. So that is essentially the growth drivers for the next four quarters.”

Chigurupati mentioned a likely improvement in existing margins for the rest of the year, with a more substantial impact anticipated in the subsequent quarters as production backlogs are addressed and new launches are executed.

Read Here | Granules India gets USFDA nod for heartburn treatment drug

The Hyderabad-based pharma company reported a consolidated net profit decline of nearly 30%, amounting to ₹102 crore for the September quarter, compared to ₹145 crore in the same period the previous year. However, the company's total income increased by 3% to ₹1,191 crore (from ₹1,155.5 crore).

The income growth was aided by improved US sales, with a higher volume growth there year-on-year, partially offset by declines in the LATAM and European regions.

The market cap of Granules India is ₹8,670 crore and it competes with industry rivals such as Divi's Laboratories, Aarti Drugs, Atul, and Biocon.

(Edited by : Shweta Mungre)